Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance

• Status: Unknown status
• Trial end date: 2021-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This project is designed to demonstrate equivalence of Dotarem enhanced LGE-CMR (late gadolinium enhancement cardiac MRI) with Gadoviost enhanced LGE-CMR from the standpoint of visual image quality, quantitative image quality, and association with clinical outcomes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dipan Shah
• Collaborator: Guerbet
• Treatments: Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate

Criteria

Inclusion Criteria:

• Patients undergoing clinically referred CMR.

Exclusion Criteria:

1. Patients who are unable to give informed consent.

2. Individuals with severe claustrophobia.

3. Individuals unable to lie flat for 90 minutes (the anticipated amount of time to complete the MRI procedure).

4. Individuals who are pregnant.

5. Patients with implants or pacemakers.

6. Patients that have hypersensitivity to components of gadolinium.

7. Patients with renal failure.

8. Patients who had any trauma or surgery which may have left ferromagnetic material in the body.